Cocci Andrea, Bocchino Alessia Celeste, Cito Gianmartin, Lisa Antonello De, Russo Giorgio Ivan, Giudice Arturo Lo, Sessa Francesco, Viola Lorenzo, Cindolo Luca, Somani Bhaskar K, Siena Giampaolo
Department of Urology, University of Florence, Careggi Hospital, Florence, Italy.
Department of Urology, University of Cagliari, Cagliari, Italy.
Turk J Urol. 2021 Nov;47(6):452-460. doi: 10.5152/tud.2021.21128.
The aim of this study was to review the available literature on the efficacy and safety of the Rezum system for the treatment of symptomatic benign prostatic hyperplasia (BPH). A revision of literature up to January 2021 was carried out. Medline, Scopus, Web of Science, and PubMed archives were screened to identify all the relevant studies investigating the role of Rezum in the treatment of BPH. Randomized controlled trial (RCT), retrospective, prospective, observational, and comparative studies were included. Finally, 17 studies were included, five of which reporting data of a double blind Rezum RCT. Overall, 1,451 patients underwent Rezum procedure. All the studies performed a minimum of 3 months follow-up. Preoperatively, the mean International Prostate Symptom Score (IPSS) score was 19.8, mean Qmax was 9.2mL s1, and mean PVR was 142 cc. At 3 months after surgery, the mean IPSS score was 1.5, mean Qmax was 13.7mL s1, and mean PVR was 74 cc. Six studies investigated sexual function, most of them using the International Index of Erectile Function (IIEF)-5 questionnaire and a few also the Male Sexual Health Questionnaire (MSHQ). Preoperative mean IIEF-5 score was 18.5, and the mean MSHQ score was 7.4. At the 3 months follow-up, the mean IIEF-5 score was 16.4, and the mean MSHQ score was 9.62. None of the studies reported intraoperative complications. Rezum system is a novel minimally invasive treatment for symptomatic BPH using transurethral water vapor thermal energy. It represents a cost-effective and safe procedure with durable relief of lower urinary tract symptom, preservation of sexual function, low complications rate, and short recovery time.
本研究的目的是回顾关于Rezum系统治疗有症状良性前列腺增生（BPH）的疗效和安全性的现有文献。对截至2021年1月的文献进行了修订。检索了Medline、Scopus、科学网和PubMed数据库，以识别所有调查Rezum在BPH治疗中作用的相关研究。纳入了随机对照试验（RCT）、回顾性、前瞻性、观察性和比较性研究。最终，纳入了17项研究，其中5项报告了双盲Rezum RCT的数据。总体而言，1451例患者接受了Rezum手术。所有研究均进行了至少3个月的随访。术前，国际前列腺症状评分（IPSS）平均为19.8分，平均最大尿流率（Qmax）为9.2mL/s，平均残余尿量（PVR）为142cc。术后3个月，平均IPSS评分为1.5分，平均Qmax为13.7mL/s，平均PVR为74cc。六项研究调查了性功能，其中大多数使用国际勃起功能指数（IIEF）-5问卷，少数还使用了男性性健康问卷（MSHQ）。术前IIEF-5平均评分为18.5分，MSHQ平均评分为7.4分。在3个月随访时，IIEF-5平均评分为16.4分，MSHQ平均评分为9.62分。没有研究报告术中并发症。Rezum系统是一种使用经尿道水蒸气热能治疗有症状BPH的新型微创治疗方法。它是一种经济有效且安全的手术，能持久缓解下尿路症状，保留性功能，并发症发生率低，恢复时间短。
